Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.80 |
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.71 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834916 | 0.90 | FFAR1 (0.83) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8709593 | 0.89 | FFAR1 (0.81) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL22209116 | 0.88 | FFAR1 (0.76) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8648449 | 0.88 | FFAR1 (0.76) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8649544 | 0.88 | FFAR1 (0.97) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8649541 | 0.86 | FFAR1 (0.78) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL14021744 | 0.86 | CYSLTR1 (0.79) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8709596 | 0.84 | FFAR1 (0.77) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 | |
| SCHEMBL8646512 | 0.83 | CYSLTR1 (1.00) | FFAR1AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8712492 | 0.83 | CYSLTR1 (0.75) | FFAR1AKR1B1CYSLTR1CYSLTR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976052-B2 | Leukotriene synthesis inhibitors | NAEGIS PHARMACEUTICALS INC. (CA) | 2024-05-07 | — | — | US | disclosed |
| CN-113784713-A | Leukotriene synthesis inhibitors | 纳吉斯制药股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3908278-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | Naegis Pharmaceuticals Inc. (CA) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020146822-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | NAEGIS PHARMACEUTICALS INC. (CA) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146822-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | NAEGIS PHARMACEUTICALS INC. (CA) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976052-B2 | Leukotriene synthesis inhibitors | LTC4S, LTB4R2, LTA4H | FFAR1 276/4885AKR1B1 619/4885CYSLTR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.